Summary: In a small randomised trial in proliferative diabetic retinopathy with retinal detachment, adding an intravitreal dexamethasone implant to vitrectomy with silicone oil tamponade reduced recurrent preretinal and macular membranes and improved vision at one year.
PICO Summary
| Element | Detail |
|---|---|
| Population | 30 patients (34 eyes) with proliferative diabetic retinopathy and retinal detachment needing vitrectomy and silicone oil tamponade; single-centre, prospective RCT over 1 year, China. |
| Intervention | Vitrectomy with silicone oil tamponade plus a dexamethasone (Ozurdex) implant placed after vitrectomy. |
| Comparison | Vitrectomy with silicone oil tamponade alone. |
| Outcome | Preretinal proliferation progression from 1 to 12 months was lower with the implant (23.5% vs 88.2%; p<0.001), as was macular epiretinal membrane (11.8% vs 41.2%; p=0.024). Best-corrected visual acuity was better at 12 months (0.61 vs 1.02 logMAR; p=0.024), and central retinal thickness was lower at 1 and 6 months. |
Dexamethasone implant with silicone oil tamponade in PDR detachment
RCT · PDR with retinal detachment · 12 months
Adding a dexamethasone implant to vitrectomy with silicone oil tamponade markedly reduced recurrent preretinal proliferation and macular membranes and improved vision at one year, though the trial was small and single-centre.
Expert Commentary
This is a positive surgical-adjunct trial with a coherent rationale and notably large effect sizes, which is encouraging but invites measured interpretation. Proliferative diabetic retinopathy with detachment is driven by inflammation and fibrovascular proliferation, so placing a sustained-release corticosteroid implant to dampen the postoperative inflammatory cascade is biologically sensible, and the results follow the hypothesis cleanly: markedly less recurrent preretinal proliferation, fewer macular membranes, and better acuity at a year. The honest limitations are scale and setting, just 30 patients and 34 eyes at a single centre, which both limits power and inflates the precision with which any single estimate should be read, and the difference at the primary endpoint, while striking, comes from small numbers. I would also avoid asserting specific harms the abstract does not report; steroid implants carry recognised risks of raised intraocular pressure and cataract that any adopter must monitor, but those were not detailed here. Can I use this with my patients? This is a vitreoretinal surgical decision rather than one I make directly, but as an endocrinologist co-managing these patients it reinforces the value of aggressive systemic and ophthalmic control, and I would welcome larger multicentre confirmation before considering the implant a standard adjunct.
References
Cao Y, Wang B, Li M, et al. Outcome of silicone oil tamponade combined dexamethasone implantation in patients with proliferative diabetic retinopathy and retinal detachment undergoing vitrectomy: a prospective randomized controlled clinical trial. BMC Ophthalmol. 2025;25(1):523. doi:10.1186/s12886-025-04344-w